ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:Several 5‐halopyrimidinones have been shown to have many different biological activities. These include interferon induction, antitumor effects, modulation of immune responses, and polyclonal B‐cell activation. The present study was carried out to determine the effects of treatment of mice with two 5‐halopyrimidinones, 2‐amino‐5‐bromo‐6‐phenyl‐4(3H)‐pyrimidinone (ABPP) and 2‐amino‐5‐iodo‐6‐phenyl‐4(3H)‐pyrimidinone (AIPP), on the murine cytochrome P‐450 system. Administration of ABPP or AIPP to mice by a dosage regimen similar to that resulting in interferon induction by these chemicals resulted in a significant depression in liver cytochrome P‐450 levels. These results suggest that 5‐halopyrimidinones can depress cytochrome P‐450 levels and that this depression may affect the metabolism of other drugs by cytochrome P‐450.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:Interferon was administered intravenously on 3 consecutive days each week for 3 consecutive weeks in doses escalated each week from 10 to 20 to 30 megaunits (MU)/m2/day. Nine adult patients were treated, each of whom had undergone subtotal resection of a supratentorial anaplastic glioma within 3 weeks of beginning interferon treatment. Patients ranged in age from 34 to 71 years, and Karnofsky functional scores were 70 or greater. Evaluations included neurological examination, Karnofsky functional rating, computerized tomography brain scanning, and panels of hematologic, hepatic, renal, and coagulation testing. No dose‐limiting or prohibitive toxicities were encountered, and each patient received nine interferon doses as scheduled. There were no symptoms of neurologic toxicity other than transient lethargy. Chills and fever occurred in all patients, while headache, lethargy, and back pain were experienced by half. These symptoms were most pronounced with the initial dose of each week and did not intensify with dose escalation. The most frequent side effect of interferon treatment was fever, usually peaking near the end of the initial 4‐h infusion; it became less severe during the second and third weeks. Leukopenia and granulocytopenia were mild. Serum hepatic enzyme levels rose slightly during the course of interferon treatment and returned to normal after treatment was completed. Serum interferon levels reached a maximum concentration of 2,285 U/ml at the end of infusion and were proportional to the dosage. Interferon was not detectable in lumbar cerebrospinal fluid, but fluid from the tumor bed of one patient contained 120 U/ml. All patients are being followed after having received a course of radiation therapy to the head at the completion of interferon therapy. We recommend 10‐30 MU/m2daily for 3 days as a safe initial dose of interferon for Phase II clinical trials with brain tumor patients.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:This report describes a murine IgG2Amonoclonal antibody, called L22, derived by immunizations with an Epstein‐Barr virus‐negative large cell lymphoma B cell line. The antigen detected by L22 is not present on normal peripheral blood cells, but is present on cells stimulated by various mitogens. The proportion of L22+cells correlates closely with blastogenesis and125I‐uridine uptake. L22 precipitates a 89,500‐dalton antigen under reducing conditions, and a 180,000‐dalton antigen under nonreducing conditions. The immunoreactivity, molecular weight of the antigen, sequential immunodepletion, and blocking experiments suggest that L22 reacts with the transferrin receptor, although it did not specifically block transferrin. L22 reacts with a variable proportion of cells from virtually all human myeloid, lymphoid, and solid tumor cell lines tested. Expression of the antigen is relatively constant within a given cell line and varies to only a limited extent with DNA content or cell cycle. The antigen has been identified on rare lymph node cells in certain reactive and malignant conditions. The antibody reacts with a variable number of peripheral blood cells in certain cases of myeloid and lymphoid leukemias, but does not react with peripheral lymphocytes from patients with inflammatory conditions. Its reactivity suggests possible utility in subclassification of leukemias, and perhaps in immunotherapy, in view of the limited reactivity with nonproliferating cells.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:Adsorption of the plasma of Sprague‐Dawley rats having 7,12‐dimethylbenzanthracene (DMBA)‐induced primary mammary adenocarcinomas with protein A‐containingStaphylococcus aureusCowan I (SAC) and reinfusion of the adsorbed plasma caused significant (p < 0.05) regression of mammary adenocarcinomas. Adsorption of plasma was done at different intervals—weekly, biweekly, and on alternate days. Of these protocols, alternate‐day adsorptions induced very fast (within a week) tumor regression (p < 0.001). Other protocols also produced tumor regression; however, the effect was delayed. In long‐term studies, the responding animals showed fewer tumor nodules than did the untreated controls. The plasma of the treated animals showed (a) a reduction in blocking activity, (b) an increase in antibody‐ and complement‐mediated cytotoxicity, and (c) potentiation of the cytotoxic activity of peripheral blood mononuclear cells (PBMCs). Histopathological analyses of biopsied sections of tumors from treated animals showed (a) disruption of tumor cell architecture, (b) loss of glandular structure, (c) shrinkage of epithelial cells, and (d) moderate mononuclear cell infiltration. Thus, adsorption of the plasma of DMBA tumor‐bearing rats with SAC allows an indigenous immune mechanism to function against autochthonous tumors to control their growth and cause regression.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:Inevitable metastatic disease was partially controlled in Wistar/Furth rats after intraperitoneal injection of blood lymphocytes cultured with neuraminidase‐treated tumor cells and phytohemagglutinin after amputation of implanted syngeneic MT/W 449A mammary adenocarcinoma. Control of MT/W 449A metastasis was limited to animals with primary tumors weighing <700 mg. An optimal 20‐25 × 106‐lymphocyte dose gave control in 8 of 18 animals (44%). Metastasis control rate was 50% in animals with small primary tumors (<250 mg). All animals in different control groups died of metastatic disease, without significant survival differences among overall groups or tumor weight‐stratified subgroups. Intraperitoneal injection of neuraminidasetreated tumor cells alone did not control metastatic disease. Cell‐mediated51Cr‐release cytotoxicity indexes of test inocula were significantly predictive of longevity and survival.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:The phorbol ester 4&bgr;‐phorbol 12‐myristate 13‐acetate (PMA) was studied for its ability to induce increased lymphotoxin (LT) production from a number of continuous human B lymphoblastoid cell lines that spontaneously release low levels of LTin vitro.A 5‐20‐fold increase in LT production was seen when all seven of these cell lines were cocultured with 20 ng/ml PMA for 72 h under serum‐free conditions in 0.1% lactalbumin hydrolysate. One cell line, GM3104A, was cloned and repeatedly selected to obtain a high‐level LT producer in the presence of PMA. This subline, termed IR 3.4, spontaneously released the &agr;‐LT molecular weight (MW) class; however, upon PMA stimulation it released high levels of &agr; and an unrelated &bgr;‐LT MW class form. The increased amounts of LT released in the presence of PMA by IR 3.4 lymphoid cells provides a new method for the production of large amounts of &agr;‐LT for purification from a single cell source for biochemical and functional studies, and indicates that the type of induction signal may influence the type of LT released.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

摘要:

Summary:Studies in therapeutic immunopharmacology have identified a large array of natural and synthetic biological response modifiers (BRM) that can be entered into clinical trials. However, it is obvious that a preclinical screen is needed to limit entry of BRM into Phase I trials to those with the greatest clinical potential. In this article we discuss the development of a preclinical screen for BRM and the necessary attributes for such a screen. During the development of our preclinical screen, we noted numerous immunological and biological criteria crucial to the establishment of relevant and reproducible models of immunomodulation and immunotherapy. These or similar considerations are critical to the development of a strong scientific base needed to establish the principles of biological response modification and to allow their translation into a successful program of clinical immunotherapy.

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID

ISSN:0732-6580    

出版商:OVID    

年代:1984

数据来源: OVID